(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2016 (23.06.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/097144 A1

(51) International Patent Classification:
C07D 413/12 (2006.01) *A61K 31/506* (2006.01)
A61K 31/423 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4439 (2006.01) *A61P 31/00* (2006.01)
A61K 31/501 (2006.01) *A61P 1/00* (2006.01)

(21) International Application Number:
PCT/EP2015/080221

(22) International Filing Date:
17 December 2015 (17.12.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1422727.6 19 December 2014 (19.12.2014) GB
1508866.9 22 May 2015 (22.05.2015) GB

(71) Applicant: **GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) Inventors: **BOUILLOT, Anne Marie Jeanne**; Laboratoire Glaxosmithkline S.A.S., Centre de Recherches, 25 Avenue du Quebec, ZA de Courtaboeuf, 91951 Les Ulis (FR). **DENIS, Alexis**; Laboratoire Glaxosmithkline S.A.S., Centre de Recherches, 25 Avenue du Quebec, ZA de Courtaboeuf, 91951 Les Ulis (FR). **WALKER, Ann Louise**; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **LIDDLE, John**; Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

(74) Agent: **HILLIER, Mark**; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

[Continued on next page]

(54) Title: 3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS



(I)

(57) Abstract: Compound of formula (I) wherein R^1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or =O; and R^2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disewase, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

WO 2016/097144 A1

Published:

— *with international search report (Art. 21(3))*